Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical India United States

CRO Inspection Fall-Out: Semler's Clients Have To Repeat Studies

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Data integrity spotlight expands beyond cGMP as FDA finds Semler manipulated study subject samples in bioequivalence studies conducted at its Bangalore facility.

Table

View full table

Advertisement

Related Content

Generics Bulletin
Data Integrity: US FDA Seeks Dismissal Of CRO Semler’s Lawsuit For Lost Business
Pink Sheet
Data Integrity: US FDA Seeks Dismissal Of CRO Semler’s Lawsuit For Lost Business
Generics Bulletin
The Case Of The Suspect Spreadsheet: Semler Sues US FDA Over Data Integrity Concerns
Pink Sheet
The Case Of The Suspect Spreadsheet: Semler Sues US FDA Over Data Integrity Concerns
Pink Sheet
WHO Tackles Submission Of Insufficient Or False Data By Pharma
Scrip
Foreign Regulators Rap More Indian Firms Over Data Integrity
Pink Sheet
Watson’s Bupropion XL Undone By Outlier Patient, Bankrupt CRO
Pink Sheet
Cetero Fallout: Five Years Of Potentially False Data Creates Three Tough Options For Sponsors

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical India United States
UsernamePublicRestriction

Register

PS079342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By